Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study

被引:14
作者
Fanciullino, Raphaelle
Evrard, Alexandre
Cuq, Pierre
Giacometti, Sarah
Peillard, Laurent
Mercier, Cedric
Aubert, Claude
Milano, Gerard
Ciccolini, Joseph
机构
[1] Sch Pharm, Pharmacokinet Dept, Marseille, France
[2] Sch Pharm, Toxicol Unit, Montpellier, France
[3] Ctr Antoine Lacassagne, Oncopharmacol Unit, Nice, France
关键词
5-fluorouracil; HT29; metabolism; resistance; thymidine kinase; thymidylate synthase;
D O I
10.1097/01.cad.0000198914.83195.61
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pro-drug 5-fluorouracil (5-FU) exerts its anti-proliferative action after conversion into cytotoxic metabolites. We previously demonstrated that the anti-cancer action of 5-FU could be enhanced by boosting thymidine phosphorylase (TP) activity in cancer cells, the first step of the DNA pathway, that yields the critical anti-thymidylate synthase (TS) fluorodeoxyuridine monophosphate (FdUMP) metabolite. In the present study, we further studied to what extent 5-FU activity could be optimized by overexpressing cancer cell thymidine kinase (TK), the second step of the DNA pathway, for which controversial data have been published so far. Additionally, screening of biochemical modulators likely to contribute to 5-FU activation was also carried out. TK-overexpressing colorectal cells were obtained after designing vectors harboring viral and human cDNA, and performing stable transfection in the human HT29 cell line. Anti-proliferative assays were subsequently performed so as to evaluate change in cell sensitivity to 5-FU, and metabolism monitoring was carried out to follow drug activation and HUMID formation after cellular uptake. Finally, TS inhibition was assessed as a pharmacological endpoint. Results showed that overexpression of TK led to a marked desensitization of our model. A negative correlation (r(2)=0.87) was found between the level of TK activity and 5-FU anti-proliferative action - the higher the activity, the lower the sensitivity. Of the various drugs screened as putative modulators, only those involved in TP activity proved to enhance 5-FU efficacy via optimized FdUMP formation. Conversely, genetically increasing TK activity did not modify 5-FU activation pathway nor subsequent TS inhibition in our model. Therefore, our results indicate that TK is not a limiting step in the production of anti-TS HUMP and that tumor cells overexpressing TK are likely to resist 5-FU-based chemotherapies.
引用
收藏
页码:463 / 470
页数:8
相关论文
共 41 条
  • [1] Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs
    Ackland, SP
    Peters, GJ
    [J]. DRUG RESISTANCE UPDATES, 1999, 2 (04) : 205 - 214
  • [2] BERGER SH, 1984, MOL PHARMACOL, V25, P303
  • [3] Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
    Braybrooke, JP
    Propper, DJ
    O'Byrne, KJ
    Koukourakis, MI
    Patterson, AV
    Houlbrook, S
    Love, SD
    Varcoe, S
    Taylor, M
    Ganesan, TS
    Talbot, DC
    Harris, AL
    [J]. BRITISH JOURNAL OF CANCER, 2000, 83 (02) : 219 - 224
  • [4] Thymidine kinase as a proliferative marker:: Clinical relevance in 1,692 primary breast cancer patients
    Broët, P
    Romain, S
    Daver, A
    Ricolleau, G
    Quillien, V
    Rallet, A
    Asselain, B
    Martin, PM
    Spyratos, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) : 2778 - 2787
  • [5] Uridine phosphorylase - An important enzyme in pyrimidine metabolism and fluoropyrimidine activation
    Cao, DL
    Pizzorno, G
    [J]. DRUGS OF TODAY, 2004, 40 (05) : 431 - 443
  • [6] Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells
    Chung, YM
    Park, SH
    Park, JK
    Kim, YT
    Kang, YK
    Yoo, YD
    [J]. CANCER LETTERS, 2000, 159 (01) : 95 - 101
  • [7] Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study
    Ciccolini, J
    Peillard, L
    Aubert, C
    Formento, P
    Milano, G
    Catalin, J
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2000, 14 (02) : 147 - 154
  • [8] Ciccolini J, 2001, MOL CANCER THER, V1, P133
  • [9] Ciccolini J, 2002, MOL CANCER THER, V1, P923
  • [10] Ciccolini J, 2000, CLIN CANCER RES, V6, P1529